

AD _____

Award Number: DAMD17-03-1-0654

TITLE: Development of Peptide Antagonists of Chemokine Receptors
Involved in Breast Cancer Metastasis

PRINCIPAL INVESTIGATOR: Sylvie E. Blondelle, Ph.D.

CONTRACTING ORGANIZATION: Torrey Pines Institute for Molecular
Studies
San Diego, California 92121

REPORT DATE: March 2005

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050630 044

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE March 2005	3. REPORT TYPE AND DATES COVERED Final (1 Sep 2003 - 28 Feb 2005)	
4. TITLE AND SUBTITLE Development of Peptide Antagonists of Chemokine Receptors Involved in Breast Cancer Metastasis			5. FUNDING NUMBERS DAMD17-03-1-0654	
6. AUTHOR(S) Sylvie E. Blondelle, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Torrey Pines Institute for Molecular Studies San Diego, California 92121 E-Mail: sblondelle@tpims.org			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Breast cancer cells were shown to express functionally active chemokine receptors that may promote metastasis, and an anti-human CXCR4 chemokine receptor monoclonal antibody was found to reduce the level of lung metastasis by 61-68 percent. Based on these findings supporting the role for chemokine ligand-receptor interactions in promoting metastasis of breast cancer, we develop small molecule antagonists to CXCR4. This was accomplished by screening in a competitive assay synthetic combinatorial libraries (SCLs) made up of D-amino acid peptides for their ability to antagonize CXCR4 receptor function using HeLa cells and PBMC cells (used as standard), and breast cancer cells (MDA-MB-231 and DU4475, known to express CXCR4), and a monoclonal antibody anti-CXCR4 known to block chemotaxis induced by CXCL12 (formerly known as SDF1- α). The SCL approach, particularly when generated in a positional scanning (PS) format, allows the direct identification of the key residue(s) of active peptide sequence(s) from the library screening. Following the screening of a library, candidate sequences were synthesized and their inhibitory activity on the binding of anti-CXCR4 antibody was evaluated as well as their ability to abrogate the migratory response of cells induced by SDF-1 α .				
14. SUBJECT TERMS CXCR4 antagonists				15. NUMBER OF PAGES 10
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	9
Reportable Outcomes.....	9
Conclusions.....	9
References.....	10

INTRODUCTION

Breast cancer cells were recently reported to express functionally active chemokines that may promote metastasis (1). Specifically, chemokines (e.g., SDF-1 α) and their receptors (e.g., CCR7 and CXCR4) are now believed to play a critical role in motility, homing, and proliferation of cancer cells at specific metastatic sites. For instance, the signaling pathways activated upon interaction of CXCR4 with SDF-1 α play a role in the survival and proliferation of cancer cells once they are localized in a specific organ. These *in vitro* and *in vivo* inhibition studies make CXCR4 a potential target for preventing the conversion of premalignant to invasive breast cancer. The overall aim of this proposal was therefore to develop small molecule chemokine antagonists that can be used as simple model systems to further understand the role of chemokine ligand-receptor interactions in breast cancer evolution, as well as lead compounds for potential treatment against metastatic breast tumors. This was accomplished by using a synthetic combinatorial library (SCL) approach to identify D-amino acid hexa- and decapeptides that block the anti-CXCR4 antibody binding to CXCR4-expressing cells. D-peptides, by their nature, are much more stable to proteolysis and immune clearance and are attractive alternate drug candidates to natural L-peptides.

RESEARCH ACCOMPLISHMENTS

Task 1: To determine the experimental conditions for an optimal detection of CXCR4 expression by flow cytometry

The detection of CXCR4 recognition by Cy-chrome labeled anti-CXCR4 mAb 12G5 (Pharmingen, San Diego, CA) was evaluated by flow cytometry for two breast cancer cell lines, MDA-MB-231, known to express CXCR4 (2) and MDA-MB-468, a CXCR4-deficient cell line (1) used as negative control, as well as for HeLa cell line and peripheral blood mononuclear cells (PBMCs) from healthy volunteers, used as positive controls. The corresponding isotype IgG2a was used as a negative control to subtract non-specific binding. A 30 min incubation at room temperature of 2×10^6 cells with 5 μ l mAb resulted in 8% and 4% specific recognition for MDA-MB-231 and MDA-MB-468 cells, respectively, and 80 to 85% specific recognition for HeLa and PBMCs. The low recognition of the MDA cells observed in our flow cytometry measurements agrees with a recent finding reported by Helbig et al. (3) that less than 10% of MDA-MB-231 cells grown in culture express CXCR4 on their surface. A prerequisite to identify individual active compounds from mixture-based combinatorial libraries is a significant signal to noise ratio. Due to the low expression of CXCR4 on MDA cells, we selected to use PBMCs as standard cells to develop CXCR4 antagonists from libraries and evaluate the antagonistic activity of the best candidates with breast cancer cells.

Task 2: To screen two peptide synthetic combinatorial libraries for their ability to antagonize CXCR4 receptor function


The libraries used in these studies are mixture-based SCLs and represent collections of peptides that are screened as mixtures of soluble compounds [i.e., not attached to solid supports (4)]. They were generated in a positional scanning (PS) format, which allows the determination of key residues at all

Table 1. Hexapeptide PS-SCL description

- 6 diversity positions	- 20 D-amino acids at each defined position (o)
- 1 defined position	- 19 D-amino acids at each mixture position (x - no D-cysteine)
- 6 sublibraries	
Ac-oxxxxx-NH ₂	- 20 mixtures per sublibrary
Ac-xoxxxx-NH ₂	- $6 \times 20 = 120$ mixtures to be tested
Ac-xxoxxx-NH ₂	- $19^5 \sim 2.5 \times 10^6$ peptides per mixture
Ac-xxxoxx-NH ₂	- $20 \times 19^5 \sim 5 \times 10^7$ peptides in entire library
Ac-xxxxox-NH ₂	

diversity positions in a single screening assay (5). Thus, a PS-SCL is composed of sublibraries, each addressing a position in a peptide sequence. The data derived from each sublibrary yield information about the key residue(s) for each position. If the key

Figure 1. Inhibition of CXCR4 recognition by each mixture making up the D-amino acid hexapeptide library. Each graph represents the inhibitory activity of a given sublibrary. Each bar represents the percent inhibition of a mixture defined with the amino acid listed on the x-axis at 100 μ g/ml. The horizontal line represents the average percent inhibition plus 1.5 standard deviation value for all mixtures present in a given sublibrary and is used to differentiate those mixtures having significant activity relative to the others. The hollow bars represent the mixtures that were selected to carry out the deconvolution process.



sequences having an alanine at position 1, and mixture number 120 was defined with tyrosine at position 6 (Ac-xxxxxy-NH₂), i.e., contains all possible hexapeptide sequences having a tyrosine at position 6. Therefore, each individual hexapeptide was present in 6 separate mixtures, each one differing from the position of the fixed amino acid. All 120 mixtures were mixed with PBMCs and the recognition of cell-surface coreceptors by a monoclonal antibody specific for CXCR4 was monitored by FACS as follows. 6×10^5 cells/ml PBMCs that were pre-activated with human recombinant IL-2 (Pharmingen, San Diego, CA) for 8-12 days were incubated with peptide mixtures for 30 min at 37°C under 5% CO₂ atmosphere in FACS solution (PBS, 0.1% BSA, 0.1% Na azide) followed by a 30 min incubation at room temperature with 10 μ l of anti-CXCR4 mAb 12G5. The corresponding isotype IgG2a was used in all experiments. The cells were washed with 2 ml of FACS solution, resuspended in 0.5 ml of FACS solution, and analyzed using a FACScallibur (Becton Dickinson). The specific fluorescence corresponding to the cell surface molecule was calculated as median of all positive events subtracting the fluorescence of the isotype control.


As shown in Figure 1, a limited number of mixtures exhibited antagonistic activity, indicating the presence of a limited number of active sequences within the library. The next step following the screening of a PS-SCL is to synthesize all sequences corresponding to all possible combinations of the amino acids defining the most active mixtures from each sublibrary. We selected mixtures that inhibit CXCR4 recognition at a percentage above the average plus 1.5 standard deviation value within each sublibrary in a

residue(s) at each position represent the same active peptide(s) present in the corresponding mixtures, then combinations of these residues lead to active individual peptides.

The first library to be screened was made up of D-amino acid hexapeptides as described in Table 1. Thus, each mixture was defined by a single D-amino acid ("o" position) while the five other positions ("x" position) were a mixture of 19 D-amino acids; D-cysteine was omitted to avoid polymerization. For example, the first mixture was defined with alanine at position 1 (Ac-xxxxxx-NH₂), i.e. contained all possible hexapeptide

manner that the amino acids defining those mixtures were of different chemical character (hollow bars in Fig. 1). For example, only one of the two mixtures defined with tyrosine or tryptophan were selected at positions 1, 4, 5, and 6. This led to the generation of 36 individual peptides ($2 \times 1 \times 1 \times 2 \times 3 \times 3 = 36$). In addition, a number of arginine/tyrosine L- and D-amino acid hexapeptides that were generated for an unrelated study were selected for further evaluation as described below. Similarly to known CXCR4 antagonists, the D-hexapeptides to be synthesized and/or tested have a cationic character. The site of recognition in the extracellular domain of CXCR4 that can be blocked with the mAb 12G5 includes an anionic region (6), which could interact with cationic peptides.

Figure 2. Inhibition of CXCR4 recognition by each mixture making up the D-amino acid decapeptide library.



Since the 9-mer poly-D-arginine ALX 40-4C (7) and 10-mer D-peptides derived from SDF-1 α (8) were shown to inhibit HIV-1 entry by targeting CXCR4, we also initiated the screening of a D-amino acid decapeptide PS-SCL. This library was built in a manner similar to the hexapeptide library described above (Ac-oxxxxxxxxx-NH₂ to Ac-xxxxxxxxxo-NH₂) and consisted of 200 separate mixtures arranged in 10 sublibraries. Each mixture contained 3.2×10^{11} (19^9) different peptides in approximately equimolar concentration, and the entire decamer library contained a total of 6.5×10^{12} (20×19^9) different individual decapeptides. Three sublibraries were tested so far in a manner similar to the hexapeptide SCL (Fig. 2). As for the hexapeptide library, the most active mixtures are mostly defined with basic residues (arginine or lysine) or tyrosine. While the screening of the library will be completed in the near future, a number of arginine/tyrosine D-amino acid decapeptides that were generated for an unrelated study were selected for further evaluation as described below.

Task 3: To synthesize candidate peptide sequences

All individual peptides were synthesized by simultaneous solid-phase technology using standard t-Boc chemistry and p-methylbenzylamine resin (0.81mcq/g, 100-200 mesh), which was contained within a sealed polypropylene mesh packet (9). Final cleavage and deprotection steps were carried out with liquid hydrogen fluoride (HF) using a "low-high" HF cleavage protocol (10,11). The identity and purity of the peptides were analyzed by mass spectral analysis interfaced with a liquid chromatography system (Finnigan LCQ) and analytical reversed phase high performance liquid chromatography (RP HPLC) using a Beckman System Gold HPLC. The peptides were purified by preparative RP HPLC using a Waters Milliprep 300 preparative HPLC with a Foxy fraction collector.

Task 4: To determine the antagonistic activity of the candidate peptides


Table 2. Active hexapeptides toward PBMCs

	% Inhibition at		
	1,000 ng/ml	100 ng/ml	10 ng/ml
Ac- R R W W R R -NH ₂	81%	65%	18%
Ac- R R W W C R -NH ₂	76%	16%	--
Ac- r r w w c r -NH ₂	75%	12%	--
R R Y W W R -NH ₂	63%	26%	--
Ac- R R K W R F -NH ₂	62%	19%	--
Ac- R R R R R R -NH ₂	58%	6%	--
Ac- R R W W R F -NH ₂	53%	37%	--

In a first experiment, the 36 D-amino acid hexapeptides derived from the library were assayed for inhibition of CXCR4 recognition using PBMCs by flow cytometry. As shown in Figure 3, the most active peptides exhibit 65 to 83% CXCR4 recognition at 1 μ g/ml.

In parallel, 14 L- or D-amino acid hexapeptides derived from unrelated studies were

Figure 3. Inhibition of CXCR4 recognition in PBMCs by individual D-hexapeptides as determined by flow cytometry




#		% Inhibition
21	Ac- y h r w r w -NH ₂	83%
30	Ac- y h r y r w -NH ₂	81%
3	Ac- r h r w r w -NH ₂	70%
29	Ac- y h r y r r -NH ₂	65%

similarly tested. The most active peptides are listed in Table 2. The most active L-amino acid hexapeptides inhibited CXCR4 recognition with an EC₅₀ value of 37 ng/ml.

Similarly, a set of D-amino acid decapeptides were assayed for inhibition of CXCR4 recognition. The most active peptide (D13-rr) exhibited antagonistic activity with EC₅₀ at 29 nM levels (Fig. 4). D10-rr and D16-rr were similarly effective while D5-rr exhibited a 10-fold lower activity (EC₅₀ values of 233 nM – Fig. 4).

Figure 4. Inhibition of CXCR4 recognition in PBMCs by D-decapeptides



Name	Sequence
D5-rr	Ac-rrwrrriyrr-NH ₂
D9-rr	Ac-rrwrrriyyr-NH ₂
D10-rr	Ac-sfmyrrwrrr-NH ₂
D13-rr	Ac-rrmyrrriyr-NH ₂
D16-rr	Ac-rrmyryhrui-NH ₂

Figure 5. ELISA for determination of inhibition of CXCR4 recognition






Figure 6. Inhibition of CXCR4 recognition in HeLa cells by individual D-hexapeptides as determined by ELISA.



#		% Inhibition
20	Ac- y h r w r r -NH ₂	91%
35	Ac- y h r y y r -NH ₂	90%
29	Ac- y h r y r r -NH ₂	88%
16	Ac- r h r y y h -NH ₂	81%
15	Ac- r h r y s w -NH ₂	81%
21	Ac- y h r w r w -NH ₂	78%
3	Ac- r h r w r w -NH ₂	77%
5	Ac- r h r w s r -NH ₂	77%
2	Ac- r h r w r r -NH ₂	77%

An alternative assay to flow cytometry was investigated to determine whether the identified peptides inhibit CXCR4 recognition by mAb 12G5. An ELISA assay was set up in which the peptides were preincubated with the cells overnight at 4°C, followed by 1 hr incubation at 37°C with mAb 12G5 and the inhibition was detected using europium-labeled streptavidin. As a positive control, HeLa cells were first used to ensure detection of antagonistic activities. In this assay, D16-rr inhibited CXCR4 recognition in HeLa cells with EC₅₀ at 1.5 μ M levels, i.e., 10-fold lower than the natural ligand SDF-1 α , while D10-rr had a lower inhibitory effect than SDF-1 α (Fig. 5). Using the same experimental conditions (25,000 cells per well), a slight inhibition of CXCR4 recognition by mAb 12G5 could also be observed for D13-rr when testing MDA-MB-231 cells (Fig. 5). Optimization studies are on going to determine the experimental conditions leading to an increased detection level of inhibition.


Figure 7. Inhibition of chemotactic activity of SDF-1 α on CCRF-CEM cells in the presence of D13-rr.



The 36 D-amino acid hexapeptides derived from the library were also assayed for inhibition of CXCR4 recognition in HeLa cells by ELISA in order to confirm or contrast the inhibitory activity observed in PBMCs by flow cytometry. At 10 μ g/ml, a number of peptides had a significant effect confirming the antagonistic activity observed earlier (Fig. 6).

We also initiated studies to evaluate if the peptide candidates have antagonistic effects on the chemotaxis induced by SDF-1 α . Since CCRF-CEM cells are non-adherent CXCR4 expressing cells known to migrate, the migration of CCRF-CEM cells in the presence of D13-rr was evaluated using a Transwell system with a membrane of 5 μ m. 600 nM D13-rr could

Figure 8. Inhibition of chemotactic activity of SDF-1 α on CCRF-CEM cells



completely block the cell migration induced by 1.3 nM SDF-1 α , while partial inhibition was observed with 60 nM D13-rr (Fig. 7). These results support that the peptide interacts with CXCR4 to block the binding site of SDF-1 α or to induce a conformational change of the binding site of SDF-1 α in CXCR4.

Similarly, the most active peptides identified in each series of peptides tested were assayed for inhibition of CCRF-CEM cells migration induced by 1.3nM SDF-1 α (Fig. 8). The hexapeptide # 21 exhibit the greatest

inhibitory effect with complete inhibition at the lowest concentration tested (0.96 μ M).

KEY RESEARCH ACCOMPLISHMENTS

- Identify novel short peptides that block the recognition of CXCR4 by anti-CXCR4 mAb 12G5.
- The peptide candidates block the chemotaxis of CXCR4 expressing cells induced by the natural ligand SDF-1 α

REPORTABLE OUTCOMES

Manuscript in preparation.

CONCLUSION

Using a combinatorial library approach, we have identified cationic D-amino acid hexapeptides and decapeptides that block the anti-CXCR4 antibody binding to CXCR4-expressing cells. The unique nature of these D-peptide inhibitors (i.e., length and nature of their sequences), as well as the importance of CXCR4 on breast cancer metastasis make these peptides useful tools to further explore the elements responsible for their inhibitory activity in a structure-activity relationship (SAR) study. Such study would provide important information on how small peptides may affect SDF-1 α binding to CXCR4, and further our understanding on the role of SDF-1 α /CXCR4 interactions in the spread of breast cancer cells.

REFERENCES

1. Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S.N., Barrera, J.L., Mohar, A., Verástegui, E., Zlotnik, A. (2001) Involvement of chemokine receptors in breast cancer metastasis. *Nature* **410**:50-56.
2. Tamamura, H., Hori, A., Kanzaki, N., Hiramatsu, K., Mizumoto, M., Nakashima, H., Yamamoto, N., Otaka, A., Fujii, N. (2003) *FEBS Lett.* **550**:79-83.
3. Helbig, G., Christopherson, K.W. 2nd, Bhat-Nakshatri, P., Kumar, S., Kishimoto, H., Miller, K.D., Broxmeyer, H.E., Nakshatri, H. (2003) NF- κ B promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. *J. Biol. Chem.* **278**:21631-21638.
4. Houghten, R.A., Pinilla, C., Appel, J.R., Blondelle, S.E., Dooley, C.T., Eichler, J., Nefzi, A., Ostresh, J.M. (1999) Mixture-based synthetic combinatorial libraries. *J. Med. Chem.* **42**:3743-3778.
5. Pinilla, C., Appel, J.R., Blanc, P., Houghten, R.A. (1992) Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries. *Biotechniques* **13**:901-905.
6. Hesselgesser, J., Liang, M., Hoxie, J., Greenberg, M., Brass, L.F., Orsini, M.J., Taub, D., Horuk, R. (1998) Identification and characterization of the CXCR4 chemokine receptor in human T cell lines: Ligand binding, biological activity, and HIV-1 infectivity. *J. Immunol.* **160**:877-883.
7. Doranz, B.J., Grovit-Ferbas, K., Sharron, M.P., Mao, S.H., Goetz, B.M., Daar, E.S., Doms, R.W., O'Brien, W.A. (1997) A small-molecule inhibitor directed against chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. *J. Exp. Med.* **186**:1395-1400.
8. Zhou, N., Luo, Z., Luo, J., Fan, X., Cayabyab, M., Hiraoka, M., Liu, D., Han, X., Pesavento, J., Dong, C.Z., Wang, Y., An, J., Kaji, H., Sodroski, J.G., Huang, Z. (2002) Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derives from chemokines. *J. Biol. Chem.* **277**:17476-17485.
9. Houghten, R.A. (1985) General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. *Proc. Natl. Acad. Sci. USA* **82**:5131-5135.
10. Tam, J.P., Heath, W.F., Merrifield, R.B. (1983) S_N2 deprotection of synthetic peptides with a low concentration of HF in dimethyl sulfide: Evidence and application in peptide synthesis. *J. Am. Chem. Soc.* **105**:6442-6455.
11. Houghten, R.A., Bray, M.K., DeGraw, S.T., Kirby, C.J. (1986) Simplified procedure for carrying out simultaneous multiple hydrogen fluoride cleavages of protected peptide resins. *Int. J. Peptide Prot. Res.* **27**:673-678.